Cellular Regulation of Fibrinolysis

Summary

By virtue of their capacity to bind plasminogen activators and plasminogen, to accelerate plasminogen activation and to protect bound plasmin from inactivation by α₂ antiplasmin, cells can harness the broad proteolytic activity of plasmin to their surface. Most cells bind plasminogen with a very high capacity, a relatively low affinity (Kd~1 εM) and recognize the lysine binding sites of the molecule. Gangliosides serve as non-protein plasminogen binding sites, and a subset of membrane proteins with carboxy-terminal lysine residues also serve as receptors. The alpha isoform of enolase possesses a carboxy-terminal lysine and is a prominent plasminogen binding protein of cells. Cells of the monocytoid lineage, including peripheral blood monocytes, can markedly upregulate their expression of plasminogen receptors. The capacity to modulate expression of receptors for fibrinolytic components establishes an additional mechanism by which the cell-surface regulates the function of the plasminogen system.

• References

• 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89
• 2 Harpel PC, Chang T-S, Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen of plasma fibrin I. J Biol Chem 1985; 2 60#7 4432-4440
• 3 Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549-550
• 4 Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 2: 73-84
• 5 Miles LA, Plow EF. Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988; 2: 61-71
• 6 Hajjar KA, Hamel NM, Harpel PC, Nachman RL. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-1719
• 7 Verrall S, Seeds NW. Characterization of ¹²⁵I-tissue plasminogen activator binding to cerebellar granule neurons. J Cell Biol 1989; 109: 265-271
• 8 Beebe DP. Binding of tissue plasminogen activator to human umbilical vein endothelial cells. Thromb Res 1987; 46: 241-254
• 9 Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303-4311
• 10 Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986; 261: 11656-11662
• 11 Stephens RW, Pollanen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen E-M, Ronne E, Behrendt N, Dano K, Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-1995
• 12 Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. J Biol Chem 1989; 264: 2185-2188
• 13 Stricker RB, Wong D, Tak Shiu D, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminoagen activator on normal and thrombasthenic platelets: Effects on surface proteins and platelet aggregation. Blood 1986; 68: 275-280
• 14 Camacho M, Fondaneche M-C, Burtin P. Limited proteolysis of tumor cells increase their plasmin-binding ability. FEBS Lett 1989; 245: 21-24
• 15 Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: Identification of alpha-Enolase as a candidate plasminogen receptor. Biochemistry 1991; 30: 1682-1691
• 16 Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-2420
• 17 Bauer PI, Machovich R, Buki K, Csonka E, Koch S, Horvath I. Interaction of plasmin with endothelial cells. Biochem J 1984; 218: 119-124
• 18 Burtin P, Fondaneche M-C. Receptor for plasmin on human carcinoma cells. J Natl Cancer Inst 1988; 80: 762-765
• 19 Salonin E-M, Saksela O, Vartio T, Vaheri A, Nielsen LS, Zeuthen J. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem 1985 260.
• 20 Goldfarb RH, Liotta L. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 1986; 12: 294-307
• 21 Paranjpe M, Engel L, Young N, Liotta LA. Activation of human breast carcinoma collagenase through plasminogen activator. Life Sci 1980; 26: 1223-1231
• 22 Gavrilovic J, Murphy G. The role of plasminogen in cell-mediated collagen degradation. Cell Biol Int Rep 1989; 13: 367-375
• 23 Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989; 109: 1-6
• 24 Schlechte W, Murano G, Boyd D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 1989; 49: 6064-6069
• 25 Cohen RL, Shuman MA. Tumor cells utilize cell-bound plasmin to degrade basement membranes. Clin Res 1990; 38: 466A
• 26 Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thromb Haemost 1987; 58: 936-942
• 27 Miles LA, Levin EG, Plescia J, Collen D, Plow EF. Plasminogen receptors, urokinase receptors and their modulation on human endothelial cells. Blood 1988; 72: 628-635
• 28 Hajjar KA, Nachman RL. Endothelial cell-mediated conversion of glu-plasminogen to lys-plasminogen. J Clin Invest 1988; 82: 1769-1778
• 29 Gonias SL, Braud LL, Geary WA, VandenBerg SR. Plasminogen binding to rat hepatocytes in primary culture and to thin slices of rat liver. Blood 1989; 74: 729-736
• 30 Plow EF, Miles LA. Plasminogen receptors in the mediation of pericellular proteolysis. Cell Diff Dev 1991 (In Press)
• 31 Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasmimogen and their function in plasma. J Biol Chem 1988; 263: 11928-11934
• 32 Adelman B, Rizk A, Hanners E. Plasminogen interactions with platelets in plasma. Blood 1988; 72: 1530-1535
• 33 Miles LA, Ginsberg MH, White JG, Plow EF. Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest 1986; 77: 2001-2009
• 34 Ryan TJ, Detmar DP, Perera TB. The effect of binding to U937 cells on the proteolytic activity of human plasmin. Fibrinolysis 1990; 4 (Suppl 3) 178
• 35 Hall SW, VandenBerg SR, Gonias SL. Plasminogen carbohydrate side chains in receptor binding and enzyme activation: A study of C6 glioma cells and primary cultures of rat hepatocytes. J Cell Biochem 1990; 43: 213-227
• 36 Hall SW, VandenBerg SR, Gonias SL. Plasminogen carbohydrate side chains in receptor binding and enzyme ativation: A study of C6 glioma cells and primary cultures of rat hepatocytes. Blood 1989; 74 Suppl. 1 96a
• 37 Silverstein RL, Friedlander Jr RJ, Nicholas RL, Nachman RL. Binding of lys-plasminogen to monocytes/macrophages. J Clin Invest 1988; 82: 1948-1955
• 38 Gonzales-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry 1989; 28: 2374-2377
• 39 Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990; 86: 107-112
• 40 DesJardin LE, Boyle MDP, Lottenberg R. Group A streptococci bind human plasmin but not other structurally related proteins. Thromb Res 1989; 55: 187-193
• 41 Ullberg M, Kronvall G, Karlsson I, Wiman B. Receptors for human plasminogen on gram-negative bacteria. Infect Immun 1990; 58: 21-25
• 42 Kuusela P, Saksela O. Binding and activation of plasminogen at the surface of Staphylococcus aureus—Increase in affinity after conversion to the Lys form of the ligand. Eur J Biochem 1990; 193: 759-765
• 43 Miles LA, Dahlberg CM, Levin EG, Plow EF. Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these components to cells. Biochemistry 1989; 280: 9337-9343
• 44 Sugiyama N, Sasaki T, Iwamoto M, Abiko Y. Binding site of alpha2-plasmin inhibitor to plasminogen. Biochim Biophys Acta 1988; 952: 1-7
• 45 Hortin GL, Gibson BL, Fok KF. alpha2-antiplasmin's carboxy-terminal lysine residue is a major site of interaction with plasmin. Biochem Biophys Res Commun 1988; 155: 591-596
• 46 Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA. Nucleotide sequence of human monocyte interleukin 1 precurson cDNA. Proc Natl Acad Sci USA 1984; 81: 7907-7911
• 47 Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz D, Fiddes JC. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986; 233: 545-548
• 48 Stopelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-4943
• 49 Li H, Lu H, Mirshahi Mc, Soria J, Mishal Z, Dosquet-Bernard C, Caen JP, Soria C. 1-25 OH vitamin D3 enhances plasmin generation on monoblastic cell line. Fibrinolysis 1988; 2 Supp. 1 151
• 50 Felez J, Miles LA, Plescia J, Plow EF. Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J Cell Biol 1990; 111: 1673-1683